检索结果 - Laurence Albigès
- Showing 1 - 20 results of 105
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events 由 Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch
出版 2020Revisão -
11
-
12
-
13
-
14
-
15
-
16
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) 由 Yohann Loriot, Diletta Bianchini, E. Ileana, Shahneen Sandhu, Anna Patrikidou, Carmel Pezaro, Laurence Albigès, Gerhardt Attard, Karim Fizazi, Johann S. de Bono, Christophe Massard
出版 2013Artigo -
17
Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience 由 Baptiste Bonnet, Louis Tournier, Frédèric Deschamps, Steven Yevich, Aurélien Marabelle, Caroline Robert, Laurence Albigès, Benjamin Besse, V Bonnet, Thierry de Baère, Lambros Tselikas
出版 2024Artigo -
18
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma 由 Anthony Saroufim, Yosra Messai, Meriem Hasmim, Nathalie Rioux, Roberto Iacovelli, G. Verhoest, Karim Bensalah, J-J Patard, Laurence Albigès, Bruno Azzarone, Bernard Escudier, Salem Chouaı̈b
出版 2014Artigo -
19
Chk1 as a new therapeutic target in triple-negative breast cancer 由 Laurence Albigès, Aïcha Goubar, Véronique Scott, Cécile Vicier, Céline Lefèbvre, Samar Alsafadi, Frédéric Commo, Mahasti Saghatchian, Vladimir Lazar, Philippe Dessen, Suzette Delaloge, Fabrice André, Virginie Quidville
出版 2014Artigo -
20
Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors 由 Sarah C. Markt, Carlos Lago‐Hernandez, Rowan Miller, Brandon A. Mahal, Brandon Bernard, Laurence Albigès, Lindsay A. Frazier, Clair J. Beard, Alexi A. Wright, Christopher J. Sweeney
出版 2016Artigo
相关主题
Medicine
Internal medicine
Oncology
Renal cell carcinoma
Cancer
Immunotherapy
Sunitinib
Urology
Nivolumab
Biology
Cancer research
Gastroenterology
Confidence interval
Hazard ratio
Axitinib
Surgery
Clear cell renal cell carcinoma
Clinical trial
Genetics
Immunology
Kidney cancer
Pathology
Adverse effect
Disease
Gene
Biochemistry
Clinical endpoint
Ipilimumab
Cabozantinib
Immune system